BioTechne Corp (TECH)
(Delayed Data from NSDQ)
$71.73 USD
-2.26 (-3.05%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $71.72 -0.01 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.73 USD
-2.26 (-3.05%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $71.72 -0.01 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth D Momentum F VGM
Zacks News
New Strong Sell Stocks for October 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)
by Zacks Equity Research
Momentum stock investors will love Bio-Techne (TECH) seeing its favorable price performance both in short and long term.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?
by Zacks Equity Research
Bio-Techne (TECH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment
by Zacks Equity Research
Bio-Techne (TECH) introduces a multi-analyte cartridge format for the Ella immunoassay platform. The cartridge provides more accurate results at a lower cost.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex Corp (LMNX) is focusing on augmenting its portfolio strength through new FDA approvals.
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.
Can Stratasys (SSYS) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Launching innovative products, strategic partnerships and acquisitions, along with improving cost efficiencies are likely to are likely to strengthen Stratasys' (SSYS) Q2 results.
Should You Buy Bio-Techne (TECH) Ahead of Earnings?
by Zacks Equity Research
Bio-Techne (TECH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CyberArk Software (CYBR) Q2 Earnings: Likely to Disappoint?
by Zacks Equity Research
CyberArk Software's (CYBR) slowdown in revenue growth, competition from peers and uncertain macroeconomic environment are likely to remain headwinds in Q2.
4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
by Arpita Dutt
Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.
Implied Volatility Surging for Bio-Techne (TECH) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Bio-Techne (TECH) shares as it has huge implied volatility.
Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
by Zacks Equity Research
Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.